About Aevitas TherapeuticsAevitas Therapeutics, Inc. (“Aevitas”), develops novel gene therapy approaches for complement-mediated diseases. Aevitas is a subsidary company of Fortress Biotech Inc.
3 articles with Aevitas Therapeutics
2/26/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer.
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, To Develop Novel AAV Gene Therapy Treatments For Complement-Mediated Diseases